# JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)

An International Scholarly Open Access, Peer-reviewed, Refereed Journal

# PHARMACOVIGILANCE: A STATASTICAL STUDY OF ADVERSE DRUG REACTIONS OF INSULIN ANTIDIABETIC DRUG IN GANDHINGLAJ RURAL REGION

Miss. Dakshata Mahadev Patil<sup>1\*,</sup> Miss. Akanksha Maruti Karande<sup>1</sup>, Miss. Gouri Santosh Koshti<sup>1</sup>,

Mrs. Aarti Nagargoje<sup>1</sup>, Miss. Jyoti Gheji<sup>2</sup>

Student<sup>1</sup>, Assistant Peofessor<sup>2</sup>

Yashwant Redekar College of Pharmacy (B. Pharm & D. Pharm) Nesari, Kolhapur Maharashtra 416504

# ABSTRACT

Diabetes mellitus (DM) is a metabolic disorder that occurs in the body because if decreased insulin activity and insulin secretion. Pathological changes such as nephropathy, retinopathy and cardiovascular complication inevitably occur in the body with the progression of the disease. The aim was to assess the perception of risk for developing adverse drug reaction (ADRS) and knowledge in diabetic patients and why insulin causes side effects I.e., to find the adverse drug reaction insulin injection in diabetic patients. Sometimes insulin injection leads side effects like swelling of face, itching, rash, hypoglycemia, weight gain fluid retention. And that's why doesn't maintain sugar level in diabetic patients. Not cure any wounds. Like foot ulcer. It will spread because of increased level of sugar in blood. This study is important because adverse drug reaction of insulin injection identify, to avoid side effects of insulin. Patients taking insulin b injection regularly but it not shows actual effects. Due to improper guidelines to patients related to the way of insulin injection taking and duration. And diet of diabetic patients also improper site of injection it will leads the side effects. This study helps to reduce or overcome the side effects of insulin in diabetic patients. The survey was conducted in Gadhinglaj rural area (village). First of all, we selected the hospitals where diabetics patients are treated. In this survey we interacted with doctors to collect information about adverse drug reaction found in patient who are taking insulin

injection. we also find out which adverse drug reaction are frequently experienced all the data gathered. To observe some side effects of insulin injection. We came to the conclusion that diabetic patients I.e., insulin taking patients require extensive care as well as good counselling. Suggests the correct insulin injection technique is crucial for better glycemic control. Education and counselling on proper insulin pen injection technique. Give instruction to patient regarding the insulin delivery recommendation through insulin pen and current insulin injection practice.

Keywords: Diabetes mellitus, Hyperglycemia, Antidiabetic, Adverse drug reaction, Insulin Injection.

**INTRODUCTION:** The World Health Organization (WHO) defines pharmacovigilance as "The pharmacological science and activities related to the Detection, assessment, understanding and prevention of adverse of effect or any other drug related problems". Pharmacovigilance is the Process of monitoring evaluating the quality of the drug as well as recognizing preventing side effects medication "Monitoring for safety" In today, S atmosphere pharmacovigilance is pushing new frontier, Sis a good thing. Hence, we selected the topic of insulin side effects in Diabetic patients. As per the international diabetic, S federation, diabetes effects 74million adults in India of which around 40 % of them Seem to be insulin resistant. It's no longer adequate to just keep track of negative incidence, as well as efficiency and quality standard.


ADR Definition: An adverse drug reaction is a response to medicinal product which is noxious and unintended. Response in the context means that causal Relationship between medicinal product and an adverse effect is least a reasonable possibility.

#### © 2023 JETIR March 2023, Volume 10, Issue 3 DIABETES

Diabetes Mellitus also known as diabetes is a more metabolic disease which is becoming more deadly now days More people die because Of this. The disease is caused due to defect in insulin secretion. Diabetes mellitus is highly prevalent in Gadhinglaj is often needed for diabetes control. That is when pancreas does not produce sufficient Amount of insulin or when cells of body stop responding to produce insulin independent and gestational diabetes. With over million Diabetes patients, India has dubious distinction of being the diabetes capital of World. This no is rapidly increasing and as per various Estimates.

Diabetes types:

- Type 1 or insulin dependent diabetes mellitus
- Type 2 or Non-insulin dependent diabetes mellitus
- Gestational Diabetes Mellitus.



#### **Type 1 Diabetes**

In this type, Insulin is completely absent due to pancreas lacking cells or containing defective cells. It occurs in genetically susceptible Individuals and they have complications like kidney dysfunction. Nerve impairment, cardiovascular complications as well as blindness. Failure of pancreas to produce insulin results in type 1 diabetes. This is mostly seen in children so this has traditional name called juvenile

Diabetes (Type 1- dependent) People with juvenile form of diabetes are completely dependent on external insulin immune system breaks the cells in their pancreas that Generate insulin.

#### **Type 2 Diabetes**


It is characterized by reduced insulin secretion in response to glucose level and insulin resistance which leads insufficient absorption of Diabetes Glucose into the cells for energy. It usually occurs in obese individual and it suppresses the synthesis of insulin receptor. Failure of cells to respond to insulin produced. Lifestyle and genetic of person have for major role here. It Is also hereditary disease which Follows for generation. This type occurs at any stage, unfortunately even in course of childhood. Type 2 diabetes is mostly seen to Surface during early 30'sand later. Women often are diagnosed with gestational diabetes during this pregnancy period. This condition usually goes away after childbirth but in few causes, it turns into type 2 diabetes Increases thirst and urination are usual Symptoms during gestational diabetes.



Fig. no2

#### Gestational diabetes mellitus

It is defined as any degree of glucose intolerance with onset or first recognition during pregnancy irrespective of the glycemic status after delivery. Gestational diabetes has increased the risk of type 2 diabetes mellitus and heart disease later in life. Be sides these genetic defects of B cell function also causes diabetes.



#### **INSULININ DIABETES:**

Insulin is natural hormone produced by B cells of pancreas in non-diabetic individuals, the pancreas produces continuous supply of low Basal. Insulin level & spikes of insulin following meals. Increased insulin secretion following meals is responsible for the metabolic changes That occur the body transition from the post absorptive to an absorptive state. The appropriate insulin regimen for an individual patient Using should take into account the patient lifestyle, age, motivation, general health, self-management skills& treatment goals. Insulin is indispensable component of management of DM & proportion of patient using insulin vary from country to country. Correct Insulin injection technique is essential for better diabetic control. However, one of the large multinational surveys in 42 countries Showed that patient insulin injection technique was inappropriate. Studies of our countries showed a significant gap between insulin Injection administration guidelines& insulin injection.

### **MECHANISM OF ACTION OF INSULIN:**

Insulin determines bind to insulin receptor a heterotetrametric protein consisting of two extracellular alpha units & two transmembrane Beta units. The bound receptor auto phosphoryl at numerous intracellular substance such as insulin receptor substrate (IRS) Proteins, CDT, APS, SHc, Gab 1. Activation of these proteins leads to activation of downstream signalling molecule including P13 kinase Act.

## **EDUCATION OBJECTIVE:**

- The Major goals of pharmacovigilance are to demonstrate the efficacy of medication.
- Understanding the consideration underlying the initiations of insulin in diabetes.
- A study of adverse effect among people of various ages.
- Gain an insight into the specific insulin infusion technique & devices.
- Appreciate the factors important for deciding use of same in ICU settings
- Updating on the newer insulins.

| Insuline Type                    | How it is<br>delivered                          | Expiration<br>when opened                | On set       | peak                                  | duration                              |
|----------------------------------|---|--|--------------|---------------------------------------|---------------------------------------|
| Rapid Acting                     |   |  |              |                                       |                                       |
| Admelog                          | Vials and pens                                  | 28 days                                  | 15 to 30 min | 30 min 2%<br>HR                       | 4 to 5 hours                          |
| Afrezzainhaled<br>powder         | 4,8 and 12<br>unit catridges                    | 3 days                                   | 3 to 7 min   | 12 to 15min                           | 1 <sup>1</sup> / <sub>2</sub> 3 hours |
| Apidra                           | Vials and pens                                  | 28 days                                  | 10 to 20 min | 30 Min ½ HR                           | 2 to 4 hours                          |
| Fiasp                            | Vials and pens                                  | 28 days                                  | 15 to 20 min | 1 <sup>1</sup> ⁄ <sub>2</sub> 2 Hours | 5 hours                               |
| Humalog<br>U100 and<br>U200      | Vials, pens<br>cartridges for<br>refillable pen | 28 days                                  | 10 to 20 min | 30 min ½ HR                           | 3 to 5 hours                          |
| Novolog                          | Vials, pens<br>cartridges for<br>refillable pen | 28 days                                  | 10 to 20 min | 1 to 3 hours                          | 3 to 5 hours                          |
| Short acting                     |   |  |              |                                       |                                       |
| Regular                          | Vials and pens                                  | 31 to 42 days<br>depending<br>upon brand | 15 to 30 min | 2 <sup>1</sup> / <sub>2</sub> hours   | 4 to 12 hours                         |
| U <u>500(5x</u><br>Concentration | Vials and pens                                  | 28 days                                  | 30 min       | 4 to 8 hours                          | 18 to 24 hours                        |
| Intermediate<br>acting           |   |  |              |                                       |                                       |
| NPH<br>(Createdin<br>1946)       | Vials and pens                                  | 31 to 42 days<br>depending<br>upon brand | 1 to 2 hours | 4 to 12 hours                         | 14 to 24 hours                        |
| Long acting                      |   |  |              |                                       |                                       |
| Basaglar                         | Vials and pens                                  | 28 days                                  | 3 to 4 hours | No peak+                              | 11 to 24 hours                        |
| Lantus                           | Vials and pens                                  | 28 days                                  | 3 to 4 hours | No peak+                              | 11 to 24 hours                        |
| Levemir                          | Vials and pens                                  | 42 days                                  | 3 to 4 hours | No peak+                              | 6 to 23 hours                         |

#### © 2023 JETIR March 2023, Volume 10, Issue 3

#### www.jetir.org (ISSN-2349-5162)

|               |           | /             |              |                |                |
|---------------|-----------|---------------|--------------|----------------|----------------|
| Toujeo U300   | Pen only  | 42 days       | 6 hours      | No peak+       | 6 to 23 hours  |
| Treaiba, U100 | Pen only  | 56 days       | 1 hours      | 9 hours        | 36 to 42 hours |
| And U200      |           |               |              |                |                |
| Combination   |           |               |              |                |                |
| NPH/Regular   | Vials and | 31 to 42 vial | 30 min       | 50 min 2       |                |
| 70/30         | pens      | 10 D vials    |              | hours and 6 to |                |
| 10,00         | P •····   | 10 2 11415    |              | 10 hours       |                |
| Rapid acting  | Vials and | 28 D Vial 10  | 15 to 30 min | 1 to 4 hours   | 18 to 24 hours |
| 70/30         | pens      | D pen         |              |                |                |
| Rapid acting  | Vials and | 28 D Vial 10  | 15 to 30 min | 1 to 6% hours  | 12 to 24 hours |
| 75/25         | pens      | D pen         |              |                |                |
| Rapid acting  | Vials and | 28 D Vial 10  | 15 to 30 min |                |                |
| 50/50         | pens      | D pen         |              |                |                |
|               |           |               |              |                |                |

#### MATERIAL AND METHOD:

The survey was conducted at Gadhinglaj rural area (village) first of all we have selected the hospitals where the diabetic patients commonly available. In present survey, we have interacted with expert doctors to collect the information about adverse drug reaction found in patient who are under diabetic medication. After successful completion of the survey, we came to know exacts scenario about drugs adverse drug reaction, we also found out which adverse drug reaction frequently experienced.

| Sr.no | Activity                                    | Rational  |
|-------|---|---|
| 1     | selection of disease                        | now a days most population is suffering<br>from diabetes and they take insulin and it<br>shows side effects so we have selected<br>the topic to study the adverse drug reaction<br>of insulin in patients                           |
| 2     | selection of hospital                       | we have selected the hospital where diabetes patients are treated   |
| 3     | Questionnaire                               | Prepared question bank to<br>collect the datafor the doctors<br>the questions is related with<br>patients adverse drug reaction<br>found in antidiabetic<br>medication which adverse drug<br>reaction are frequently<br>Experienced |
| 4     | Preparation of adverse drug reaction report | prepare the adverse drug reaction to collect<br>information about the adverse drug<br>reaction found in patient   |
| 5     | data collection                             | data is collected with the help of survey<br>form and questionnaire   |
| 6     | study                                       | study of data of adverse drug reaction<br>records the information chart and plot the<br>graph   |
| 7     | compilation of data                         | study of patients gender, age.<br>Sugar level of the patients insulin<br>type and brands and their adverse<br>drug  |

|   |                          | reaction   |
|---|--------------------------|--|
| 8 | conclusion on that topic | Data collected and gives information abouthow to avoid insulin side effects. |

# SURVEY REPORT:

Out of a total of 500 diabetic patient who takes the insulin that attended the hospital during the study period. We found that 80 short Acting insulin patient who were taking 30 patient were taken Humulin and they having 200 -300 of 2 patient present adverse drug Reaction likewise 40 patients who were taking Novolin short acting insulin and 3 patients present with adverse drug reaction.10 patient Who were taking U500 SAI and in this type of insulin doesn't observe any side effect in patient.

For rapid acting insulin 4 out of 125 patients observed adverse drug reaction who we were taking insulin as part total 17 male patient are Observed it doesn't cause any side effects. 29 patient who were taking glusine apidra had 1 patient with adverse drug reaction. 19 patient Who were taking lispro rapid acting insulin and it doesn't show any side effects. 13 patient who were taking freeze 1 patient present with Adverse drug reaction 20 patient who were taking flaps rapid acting insulin it does not show any effects in patient.

Out of 75 patient taking intermediate acting insulins we found that 18 patient who were taking isophane had 1 patient present with Adverse drug reaction.15 patients who were taking glargine of patient present with adverse drug reaction. 19 patients taking NPH and 23 Patient staking insulin glargine bassaglar it doesn't show any side effects.

120 patients who were taking long-acting insulins. We found that 22 patients who were taking basaglar had 02 patients with adverse Drug reaction.27 patients taking degludec ,29 patients lanctus and 24 patients taking levemir it does not show any side effects. 18 Patients taking insulin glargine long-acting insulin 02 patients present with adverse drug reaction.

We found 100 patients who were taking combination type insulin 05 patients observed with adverse drug reaction.18 patients taking Novolog mix 70/25 it doesn't show any side effects. 21 patients who were taking metformin had03 patients with adverse drug Reaction.19 patients who were taking glimipride has 01 patient with adverse drug reaction.16 patients who were taking lisinopril it doesn't Show any side effects

According to our survey short acting insulin shows more side effect. Graph no 1 shows the drug and their Adr of short acting insulin. Graph no 2: Shows drug and their side effects of rapid acting insulin. Graph no 3: shows drug and their side effect intermediate acting insulin. Graph no 4: shows The Adverse drug reaction of long acting insulin. Graph no 5: shows the drug and their Adrs of combination acting insulin. Hence according to these Survey we observed insulin shows side effects and adverse drug reactions in patients.

| Sr.no | Insulin type         | Sugar level of<br>patient | Total no of patient | Total no of<br>adverse drug<br>reaction |
|-------|----------------------|---------------------------|---------------------|---|
| 1     | Short acting insulin |                           |                     |   |
|       | A) Humulin           | 150-300                   | 30                  | 2                                       |
|       | B) Novolin           | 150-300                   | 40                  | 3                                       |
|       | C)U500               | 150-300                   | 10                  | -                                       |
| 2     | Rapid Acting Insulin |                           |                     |   |
|       | A) Insuline as part  |                           |                     |   |
|       | B) Glusine apidra    | 159-300                   | 17                  | -1                                      |
|       | C) Lispro            |                           |                     |   |
|       | D) Admelog           | 200-400                   | 29                  | -2                                      |
|       | E) Afreeza           | 300-400                   | 19                  | 1                                       |

# **Observation table no.1**

# SN-2349-5162)

| 2023 JETIR March 2023, Volume 10, Issue 3 www.jetir.org (ISS |             |                           |          |                       |   |                         |               |    |          |   |
|--|-------------|---------------------------|----------|-----------------------|---|-------------------------|---------------|----|----------|---|
|  |             | F) Flasp                  |          | 150-200               |   | 13                      |               |    | -        |   |
|  |             |                           |          | 200-300               |   | 27                      |               |    | -        |   |
|  |             |                           |          | 300-400               |   | 20                      |               |    | -        |   |
|  |             |                           |          |                       |   |                         |               |    |          |   |
| 3  |             | Intermediate a insulin    | acting   |                       |   |                         |               |    |          |   |
|  |             | A) Isophaneflu<br>Novolin | ımulin   | 200-400               |   | 18                      |               |    | 1        |   |
|  |             | B) Glargine               |          |                       |   | 15                      |               |    | 1        |   |
|  |             | C)NPH                     |          | 200-400               |   | 19                      |               |    | -        |   |
|  |             | D) Insulin Gla            | rgine    | 200-400               |   | 23                      |               |    | -        |   |
|  |             | Basaglar                  | -        | 200-400               |   | 23                      |               |    |          |   |
|  |             |                           |          |                       |   |                         |               |    |          |   |
| 4  | _           | Long acting in            | nsulin   |                       |   |                         |               |    |          |   |
|  |             | A) Basaglar               | _        | 200-400               |   | 22                      |               |    | 2        |   |
|  |             | B) Degludec               | C        | 200-400               |   | 27                      |               |    | -        |   |
|  |             | C) Lantus                 |          | 200-400               |   | 29                      |               |    | -        |   |
|  |             | D) Levemir                |          | 200-400               |   | 24                      |               |    | 2        |   |
|  |             | E) Insulin Gla            | gine     | 200- <mark>400</mark> |   | 18                      |               |    | -        |   |
| 5  |             | Combination               | Acting   |                       |   |                         |               |    |          |   |
|  |             | insulin                   |          |                       |   |                         |               |    |          |   |
|  |             | A) Novolog m              | ix 70/30 | -                     |   | 18                      |               |    | 1        |   |
|  |             | B) Humalog m              | ix       | -                     |   | 26                      |               |    | 3        |   |
|  |             | 75/25                     |          |                       |   | 21                      |               |    | 1        |   |
|  |             | C) Metformin              |          | -                     |   | 19                      |               |    | -        |   |
|  |             | D) Glimepiride            | e        | -                     |   |                         |               |    | -        |   |
|  |             | E) Lisinopril             |          | -                     |   | 16                      |               |    |          |   |
| Sr.no  | Inus        | slin Drug                 | Age of   | Gender of             | A | dverse                  | Total n       | 10 | Total No |   |
|  |             | C                         | Patient  | Patient               | e | ffects                  | of<br>Detion( | L  | of ADrs  |   |
|  |             |                           |          |                       |   |                         | Patient       | IS |          |   |
| 1  | Sho<br>insu | rt acting<br>llin         |          |                       |   |                         |               |    |          |   |
|  | A) H        | Iumulin                   | 25       |                       |   |                         |               |    | 0.1      |   |
|  |             | Jovolin                   | 35 to 40 | Male                  | E | Iypoglycemic<br>effects | 30            |    | 01       |   |
|  | C)U         |                           | 35 to 40 | Male                  |   | Low blood               | 10            |    |          |   |
|  |             |                           | 30 to 40 | female                |   | sugar                   | 10            |    | 02       |   |
|  |             |                           |          |                       |   | Skin rashes             | 10            |    | 1        |   |
| 2  |             | oid Acting                |          |                       |   |                         |               |    |          | 1 |
|  | Inst        | ilin                      |          |                       |   |                         |               |    |          |   |
|  | 1           |                           | 1        | I                     |   |                         | l             |    | I        | L |

|              | Manala | 0000  | Values | 40  | 1       |
|--------------|--------|-------|--------|-----|---------|
| © 2023 JETIR | warcn  | 2023, | volume | 10, | Issue 3 |


(100 -2349-5162)

| 2023 JE | TIR March 2023, Volum           | ie 10, Issue 3 |      |                      | ww | w.jetir.org (I |
|---------|---------------------------------|----------------|------|----------------------|----|----------------|
|         | A) Insuline as part             | 30             | Male | -                    | 17 | -1             |
|         | B) Glusine apidra               | 25 to 30       | Male | Chest pain           | 29 | -2             |
|         | C) Lispro                       | 30 to 40       | Male | Swelling             | 19 | 1              |
|         | D) Admelog                      | 50 to 60       | Male | Face                 | 13 | -              |
|         | E) Afreeza                      |                | Male | -                    | 27 | -              |
|         |                                 |                |      | Upper<br>respiratory | 20 | -              |
|         | F) Flasp                        |                | Male | -                    |    |                |
| 3       | Intermediate<br>acting insulin  |                |      |                      |    |                |
|         | A)<br>Isophaneflumulin          | 40 to 50       | Male | Fluid                | 18 | 1              |
|         | Novolin                         |                |      | retension            | 15 | 1              |
|         | B) Glargine                     | 40 to 50       | Male | Musle<br>weakness    | 19 | 00             |
|         | C)NPH                           | 40 to 50       | Male | Rapid weight         |    |                |
|         | D) Insulin<br>Glargine Basaglar | 40 to 50       | Male | gain                 | 23 | 00             |
| 4       | Long acting<br>insulin          |                | K    | <b>.</b>             |    |                |
|         | A) Basaglar                     | 30 to 40       | Male | Tingling of          | 22 | 2              |
|         | B) Degludec                     | 30 to 40       | Male | hand or feet         | 22 | 2              |
|         | C) Lantus                       | 30 to 40       | Male | -                    | 24 | _              |
|         | D) Levemir                      | 30 to 40       | Male | -                    | 29 | _              |
|         | E) Insulin                      |                | Male | -                    | 18 | 2              |
|         | Glargine                        | 30 to 40       | Wide | Allergic             | 10 | 2              |
|         |                                 |                |      | reaction swelling    |    |                |
| 5       | Combination                     |                |      |                      |    |                |
|         | Acting insulin                  |                | Male | Skin                 | 18 | 1              |
|         | A) Novolog mix<br>70/30         | 40 to 50       |      | thickening           |    |                |
|         | B) Humalog mix                  | 40 to 50       | Male | -                    | 26 | -              |
|         | 75/25                           |                |      |                      |    |                |
|         | C) Metformin                    | 40 to 50       | Male | Nausea,              | 21 | 3              |
|         | D) Glimepiride                  | 40 to 50       | Male | vomiting<br>Loss of  | 19 | 1              |
|         | E) Lisinopril                   | 40 to 50       | Male | appetite             | 16 | -              |

Observation table no.2


## **Result and Discussion:**

| Sr no | Particulars             | Insulin Type | Total<br>No of<br>Patients | Total<br>No of<br>ADRS |
|-------|-------------------------|--------------|----------------------------|------------------------|
| 1     | Short Acting<br>Insulin |              |                            |                        |
|       |                         | A) Humalin   | 30                         | 2                      |
|       |                         | B) Navalin   | 40                         | 3                      |
|       |                         | C) U-500     | 10                         | 0                      |




# Graph no.1

| Sr no | Particulars             | Insulin Type      | Total<br>No of<br>Patients | Total<br>No of<br>ADRS |
|-------|-------------------------|-------------------|----------------------------|------------------------|
| 2     | Rapid Acting<br>Insulin |                   |                            |                        |
|       |                         | A) Insulin Aspart | 17                         | 0                      |
|       | E I                     | B) Glusine apidra | 29                         | 1                      |
|       |                         | C) Lispro         | 19                         | 0                      |
|       |                         | D) Admelog        | 13                         | 2                      |
|       |                         | E) Afreeza        | 27                         | 1                      |
|       |                         | I) Flasp          | 20                         | 0                      |




Graph no.2

| Sr no | Particulars  | Insulin Type                    | Total<br>No of<br>Patients | Total<br>No of<br>ADRS |
|-------|--------------|---------------------------------|----------------------------|------------------------|
|       | Intermediate |                                 |                            |                        |
| 3     | Acting       |                                 |                            |                        |
|       |              | A) Isophane Flumulin<br>novolin | 18                         | 9                      |
|       |              | B) Glargine                     | 18                         | 1                      |
|       |              | C) NPH                          | 15                         | 1                      |
|       |              | D) Insulin Glargine Basaglar    | 23                         | 0                      |




|       |             | Graph no.3         |                            |                        |
|-------|-------------|--------------------|----------------------------|------------------------|
| Sr no | Particulars | Insulin Type       | Total<br>No of<br>Patients | Total<br>No of<br>ADRS |
| 4     | Long Acting |                    |                            |                        |
|       |             | A) Basaglar        | 22                         | 2                      |
|       |             | B) degludec        | 27                         | 0                      |
|       |             | C) Lantus          | 29                         | 0                      |
|       |             | D) Levemir         | 24                         | 0                      |
|       |             | E)Insulin Glargine | 18                         | 2                      |



| Graph | no.4 |
|-------|------|
|-------|------|

| Sr no | Particulars | Insulin Type         | Total<br>No of<br>Patients | Total<br>No of<br>ADRS |
|-------|-------------|----------------------|----------------------------|------------------------|
| 5     | Combinition |                      |                            |                        |
|       |             | A) Novolog Mix70/30  | 18                         | 1                      |
|       |             | B) Humulog Mix 75/25 | 26                         | 0                      |
|       |             | C) Metformin         | 21                         | 3                      |
|       |             | D) Glimipiride       | 19                         | 1                      |
|       |             | E) usinopril         | 16                         | 0                      |





We come to the conclusion in the case of short acting insulin shows side effects, also other insulin shows side Effects. hence according to our survey correct insulin technique, patient counselling is important to avoid Adverse Drug reactions. Correct insulin injection technique is crucial for better glycemic control. Give instruction to patients regarding the insulin deliver Recommendation through insulin pen and current insulin injection practice. Education counselling on proper insulin pen injection technique should be provided to patients with diabetes using insulin. The insulin education that was provided to most of them was found to be Insufficient and almost ineffective there is scope of for improving these lessening injection complication and improving glycemic states. The results of the current study may serve as backbone of the template on which difference corrective strategies may be developed insufficient Future. With rapidly accumulating evidence on various aspect of diabetes care including landmark clinical trials of agents and newer Technologies. This study utilizes authorized guidelines as part of diabetes care and these updates therefore need more attention.

#### **REFERENCE:**

- 1. Augusto Pimazoni Netto6, Laurence Hirsch7 and Kenneth Strauss 8 Insulin Injection Technique Questionnaire: results of an international Study comparing Brazil, Latin America and World data Calliari et al. Diabetol Metab Syndr (2018) 10:85 <a href="https://doi.org/10.1186/s13098-018-0389-3">https://doi.org/10.1186/s13098-018-0389-3</a>
- Ramesh Sharma Poudel,1 Shakti Shrestha,2 Rano Mal Piryani,3 Bijaya Basyal,1 lah, A.W. Siddiqui, S.R. Mir, M. Ali, K.K.Pillai & Surendar Singh Antidiabetic Activity of Some Indian Medicinal Plants .To cite this article: M.R.M. Rafiullah, A.W. Siddiqui, S.R. Mir, M. Ali, K.K. Pillai & Surendar Singh (20 Kalpana Kaucha,1 and Shital Adhikari3Assessment of Insulin Injection Practice among Diabetes Patients in a Tertiary Healthcare Centre in Nepal: A Preliminary Study Hindawi Journal of Diabetes Research Volume 2017, Article ID 8648316, 6 pages <a href="https://doi.org/10.1155/2017/8648316">https://doi.org/10.1155/2017/8648316</a>
- M.R.M. Rafiul06) Antidiabetic Activity of Some Indian Medicinal Plants, Pharmaceutical Biology, 44:2,95-99, DOI;10.1080/13880200600591972International Diabetes Federation. IDF Diabetes Atlas Ninth Edition 2019. Available at: <u>www.idf.org/our-activities/advocacy-</u>Awareness/resources-and-tools/159-idf-diabetes-atlas-ninth-Edition-2019.html (accessed 28 January 2020). Abdul fatai B. Olokoba, Olusegun A. Obateru, Lateefat B. OlokobaType 2 Diabetes Mellitus:A Review of Current Trends Oman Medical Journal(2012) Vol. 27, No. 4: 269-273 DOI 10. 5001/omj.2012.68 Siddiqui NI, Kamrul-Hasan M, Hossain MA, et al. Ramadan perspective epidemiology and education in diabetes (RAPEED)study. My men singh Med J. 2017;26:256–65.
- 4. Kalra S, Mithal A, Sahay R, et al. Indian injection technique study: population characteristics and injection practices. Diabetes Ther.2017;8:637–57.
- Ripudaman Singh et al. Eur Endocrinol. 2018 Apr. A Comparison of Insulin Pen Devices and Disposable Plastic Syringes – Simplicity, Safety, Convenience and Cost Differences Eur Endocrinol.2018Apr;14(1):47-51.doi:10.17925/EE.2018.14.1.47. Epub 2018 Apr 18.
- 6. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes- 2019. Diabetes Care.2019;42(Suppl. 1):S61-70.
- 7. Puder J, Atar M, Muller B, et al. Using insulin pen needles up to five times does not affect needle tip shape nor increase pain intensity. Diabetes Res Clin Pract. 2005;67:119–23
- 8. IDFDIABETESATLAS. Eighth edition. 2019.http://www.diabetesatlas.org.Accessed 17 Dec2017.
- 9. Grassi G, Scuntero P, Trepiccioni R, et al. Optimizing insulin injection technique and its effect on blood glucose control. J Clin Transl Endocrinol. 2014;1(4):145–50.https://doi.org/10.1016/j.jcte.2014.07.006.
- Anders H Frid et al. Mayo Clin Proc. 2016 Sep. New Insulin Delivery Recommendations Mayo Clin Proc. 2016 Sep;91(9):1231-55.doi:10.1016/j.mayocp.2016.06.010
- Nakatani Y,Matsumura M, Monden T, et al. Improvement of glycemic control byre-education in insulin injection technique in patients With diabetes mellitus. Adv Ther. 2013;30(10):897 –905.https://doi.org/10.1007/s12325-013-0066
- 12. Gerich JE (1988): Glucose counter regulation and its impact on diabetes mellitus. Diabetes 37: 1608–1617.
- 13. Ahmed AM. History of diabetes mellitus. Saudi Med J 2002 Apr;23(4):373-378.
- Genetic basis of type 1 and type2 diabetes, obesity, and their complications. Advances and emerging
  opportunities in diabetes Research: a Strategic Planning report of the DMICC.
  www2.niddk.nih.gov/NR.(Accessed 22<sup>nd</sup> December
- 15. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nature Reviews endocrinology. Available at:www.nature.com/uidfinder.(Accessed 22<sup>nd</sup> December
- 16. H.Frid, G. Kreugel, G. Grassi et al., "New Insulin Delivery Recommendations," Mayo Clinic Proceedings, vol. 91, no. 9,pp. 1231–1255,2016.
- 17. Gupta A, Gupta R, Lal B (2001) Effect of Trigonella foenum-graecum (Fenugreek)seeds on glycaemic control and insulin resistance In type 2 diabetes. J Assoc Physicians India 49: 1057 -1061.

#### © 2023 JETIR March 2023, Volume 10, Issue 3

- 18. Diamond S, Matok I. Pharmacists' anticipated pain compared to experienced pain associated with insulin pen injection and fingertip. Can J Diabetes. 2011;35:282–6.
- 19. Radermecker RP,Pierad GE Scheen AJ. Lipodystrophy reaction to insulin: effects of continuous insulin and new insulin AM lin Dermatol.2007,8:21-8
- 20. Kalra S, Mithal A, Sahay R, et al. Indian injection technique study: injecting complications, education, and the health care professional. Diabetes Ther. 2017;8:659–72.
- 21. Rother KI. Diabetes treatment-bridging the divide. N Engl J Med 2007 Apr;356(15):1499-1501.
- 22. Prevalence of overweight and obesity among adults with diagnosed Diabetes United States,1988-1994 and 1999-2000"Centersfor Disease Control and Prevention(CDC) (November 2004)MMWR. Morbidity and Mortality Weekly Report; 53(45): 1066-1068.Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. In t J Clin Pract 2006 Nov;60(11):1454

